1173019-16-3
Chemical Structure
1,3-Dimethyluric acid-13C4,15N3
- CAS No.: 1173019-16-3
- Formula:C313C4H8N15N3O3
- Molecular Weight:203.11
IUPAC Name: 1,3-dimethyl-7,9-dihydro-1H-purine-2,6,8(3H)-trione-2,4,5,6-13C4-1,3,9-15N3
InChIKey: OTSBKHHWSQYEHK-JCRQFRHWSA-N
SMILES: O=[13C]1[13C]2=[13C]([15NH]C(N2)=O)[15N]([13C]([15N]1C)=O)C
Biological Activity: 1,3-Dimethyluric acid-13C4,15N3 is the 15N and 13C-labeled 1,3-Dimethyluric acid (HY-W014993). 1,3-Dimethyluric acid is a major metabolite of Theophylline (HY-B0809) in vivo. 1,3-Dimethyluric acid is an inhibitor of human organic anion transporter 1 (hOAT1) with an IC50 of 9.2 μM. 1,3-Dimethyluric acid inhibits hOAT1-mediated substrate uptake and transport through competitive binding. 1,3-Dimethyluric acid is also a component of urinary calculi. 1,3-Dimethyluric acid can be used in research on urolithiasis[1][2][3][4][5][6][7][8][9].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
1,3-Dimethyluric acid-13C4,15N3 | 1,3-Dimethyluric acid-13C4,15N3 is the 15N and 13C-labeled 1,3-Dimethyluric acid (HY-W014993). 1,3-Dimethyluric acid is a major metabolite of Theophylline (HY-B0809) in vivo. 1,3-Dimethyluric acid is an inhibitor of human organic anion transporter 1 (hOAT1) with an IC50 of 9.2 μM. 1,3-Dimethyluric acid inhibits hOAT1-mediated substrate uptake and transport through competitive binding. 1,3-Dimethyluric acid is also a component of urinary calculi. 1,3-Dimethyluric acid can be used in research on urolithiasis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Choi HD, et al. Effects of water deprivation on the pharmacokinetics of theophylline and one of its metabolites, 1,3-dimethyluric acid, after intravenous and oral administration of aminophylline to rats. Biopharmaceutics & drug disposition. 2007 Nov;28(8):445-54.
- [2]. Sugawara M, et al. Structure-affinity relationship in the interactions of human organic anion transporter 1 with caffeine, theophylline, theobromine and their metabolites. Biochim Biophys Acta. 2005 Aug 15;1714(2):85-92.
- [3]. Yoon Y, et al. Associations between CYP2E1 promoter polymorphisms and plasma 1,3-dimethyluric acid/theophylline ratios. European journal of clinical pharmacology. 2006 Aug;62(8):627-31.
- [4]. Yu SY, et al. Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: the role of CYP2E1 induction in 1,3-dimethyluric acid formation. The Journal of pharmacy and pharmacology. 2002 Dec;54(12):1687-92.
- [5]. Kuroda Y, et al. Age-Associated Theophylline Metabolic Activity Corresponds to the Ratio of 1,3-Dimethyluric Acid to Theophylline in Mice. Biological & pharmaceutical bulletin. 2019;42(8):1423-1427.
- [6]. Kim YC, et al. Pharmacokinetics of theophylline in diabetes mellitus rats: induction of CYP1A2 and CYP2E1 on 1,3-dimethyluric acid formation. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2005 Sep;26(1):114-23.
- [7]. Tang-Liu DD, et al. Nonlinear theophylline elimination. Clin Pharmacol Ther. 1982 Mar;31(3):358-69.
- [8]. Kuh HJ, et al. Nonlinear renal excretion of theophylline and its metabolites, 1-methyluric acid and 1,3-dimethyluric acid, in rats. Archives of pharmacal research. 1994 Apr;17(2):124-30.
- [9]. Safranow K, et al. Simultaneous determination of 16 purine derivatives in urinary calculi by gradient reversed-phase high-performance liquid chromatography with UV detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 May 25;819(2):229-35.
